Immunic Inc (IMUX) Receives a Buy from Chardan Capital

By Carrie Williams

Immunic Inc (IMUXResearch Report) received a Buy rating and a $40 price target from Chardan Capital analyst Taylor Feehley today.

Feehley wrote:

“We initiate coverage of Buy rating (PT$40) based on a partly derisked yet differentiated approach to treating autoimmune disease. The company’s pipeline contains 3 assets: 1) IMU-838, a dihydroorotate dehydrogenase (DHODH) inhibitor; 2) IMU-935, a RORγt inverse agonist; and 3) IMU-856, a small molecule to improve intestinal barrier function. Currently, IMU-838 is being tested in phase II trials in multiple sclerosis (MS, NCT03846219) and ulcerative colitis (UC, NCT03341962) with expansion into Crohn’s disease (CD) and primary sclerosing cholangitis (PSC, NCT03722576) anticipated shortly.”

According to TipRanks.com, Feehley has currently no stars on a ranking scale of 0-5 stars, with an average return of -20.2% and a 37.5% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Kaleido Biosciences Inc, and Evelo Biosciences Inc.

Currently, the analyst consensus on Immunic Inc is a Moderate Buy with an average price target of $40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $390 and a one-year low of $6.04. Currently, Immunic Inc has an average volume of 2.05M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.